An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies by Grasela, Thaddeus H et al.
1CHLINICAL ARMACOLOGY 
& THERAPEUTICS 
VOLUME 39 NUMBER 6 
ORIGINAL ARTICLES 
An evaluation of population 
pharmacokinetics in therapeutic trials. 
Part I. Comparison of methodologies 
JUNE 1986 
NONMEM, a computer program that uses the method of extended least-squares analysis, has been 
advocated as a means of obtaining estimates of population pharmacokinetic parameters when only 
fragmentary information can be obtained from subjects. To assess the performance of this program, we 
compared NONMEM with traditional methods for the estimation of population pharmacoldnetic 
parameters with data collected during a phase III clinical trial of alprazolam. NONMEM estimates of 
the population mean clearance and its coefficient of variation were identical to the estimates obtained 
with traditional pharmacokinetic techniques. Moreover, NONMEM estimates of these parameters 
remained stable even when as few as three data points were available per subject. NONMEM estimates 
of the mean volume of distribution and its coefficient of variation appear to be overestimated, apparently 
because of the sampling scheme used to generate data for the NONMEM analysis. Suggestions for the 
effective use of NONMEM in clinical trials, to maximize the benefits of this approach, are provided. Our 
results lend further support for the use of NON1VIEM to estimate population pharmacokinetic parame- 
ters of a drug from data generated during phase III clinical trials. (CLIN PHARMACOL THER 1986;39: 
605-12.) 
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In the past, pharmacokinetic studies have focused on 
the individual, in that studies were designed to yield 
the maximum information on the disposition of drugs 
in individual subjects. More recently, there has been 
increased interest in the determination of population 
pharmacokinetic parameters, i.e., parameters that de- 
fine the typical pharmacokinetic behavior of a drug in 
a large group of subjects or patients. 
These population pharmacokinetic parameters in- 
clude fixed effect parameters, which quantify a popu- 
lation's average kinetics (including average relation- 
ships between physiology and pharmacokinetics), and 
random effect parameters, which quantify the typical 
magnitude of random interindividual kinetic variability 
and the typical magnitude of the residual variability as 
a result of random intraindividual kinetic variability, 
drug level measurement, and model specification error. 
Estimates of these parameters have proved useful for a 
number of clinically relevant purposes, including the 
development of dosing guidelines for specific popula- 
tions of patients and the revision of dosing regimens 
by the use of measured drug concentrations.' 
Current procedures for the estimation of these pa- 
rameters involve performing traditional phannacoki- 
netic studies, after single or multiple doses, in normal 
volunteers or in patients with mild degrees of a disease 
of interest. The major problem with this approach con- 
cerns the representativeness of the information ob- 
tained, because drug disposition in patients who receive 
a drug for a therapeutic effect may be significantly 
different from drug disposition in volunteers. Unfor- 
tunately, traditional pharmacokinetic studies can be dif- 
ficult to perform in the clinical setting. Serious ethical 
problems arise when one attempts to perform these stud- 
ies in critically ill, pediatric, and elderly patients who 
may not be able to tolerate the rigors of such a study. 
This can result in a paucity of clinically relevant in- 
formation and significant delays before problems are 
recognized 
Sheiner et al.' have advocated an alternative ap- 
proach to the problem of estimating population phar- 
macokinetic parameters by the use of data generated 
during the routine clinical care of patients. This ap- 
proach, implemented in the computer program NON- 
MEM, has been shown to provide accurate and precise 
estimates of population pharmacokinetic parameters 
from such data in both simulation studies and in analysis 
of clinical data.' 
It has been proposed that this data analysis approach 
be applied to data collected during phase III and phase 
IV clinical trials to identify more quickly populations 
that are at risk for toxicity because of altered phar- 
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macokinetics. To validate this new methodology as ap- 
plied to phase III clinical trials, a series of studies are 
currently being conducted to evaluate the applicability 
and performance of NONMEM in a variety of clinical 
study settings. In addition to our present report ad- 
dressing the comparability of methodologies, other mul- 
ticenter, limited sampling studies will evaluate (1) the 
ability of NONMEM to detect potential drug-drug in- 
teractions, (2) the applicability and practicality of con- 
ducting a NONMEM analysis as an addendum to a 
large-scale clinical efficacy study, and (3) the feasibility 
and performance of NONMEM when used as a true 
pharmacokinetic screen in a long-term general patient 
population. These results will be the subject of future 
reports. Although a marketed drug will be used in all 
cases, the results should provide insights into premar- 
keting situations. 
The objectives of this study are twofold: (1) to com- 
pare NONMEM empirically with two standard methods 
for the pharmacokinetic analysis of data obtained during 
a multiple-dosing trial of alprazolam, and (2) to evaluate 
the ability of NONMEM to use fragmentary amounts 
of data per individual. This was accomplished by re- 
peating the analysis of the above data with progres- 
sively fewer data per subject. 
METHODS 
Ten healthy adult men with a mean ( :4_- SD) weight 
of 79.9 -± 44.4 kg were initially given alprazolam, 1 
mg po, followed by 0.5 mg po every 8 hours for 7 
days. 
Eighteen alprazolam plasma concentrations were 
measured after the first and last dose at 0.25, 0.5, 0.75, 
1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, and 
48 hours. In addition, 12 trough levels were measured 
from each subject during the multiple-dosing period 
(Fig. 1). 
Population pharmacokinetic parameters of alprazo- 
lam were obtained by use of the following data analysis 
procedures. 
Standard two-stage method. The Standard two-stage 
(STS) method, as the name implies, proceeds in two 
stages. In the first stage each individual's data are sep- 
arately analyzed to obtain estimates of the individual's 
pharmacokinetic parameters. For the purposes of our 
study, total body clearance (CL) was estimated after 
the first and last dose by dividing the dose by the ap- 
propriate plasma AUC. The elimination rate constant 
(lc) was estimated by least-squares regression analysis 
of the terminal log-linear decay phase. The apparent 
volume of distribution ( \lame) was then calculated as: 
Varea = CL/ke. The individual's estimated CL, ke, and 
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Fig. 1. Mean ( -± SD) alprazolam plasma concentration-time profile observed with the multiple- 
dose regimen. Alprazolam concentrations measured after the first and last doses were used for STS 
approach. Trough levels measured on days 3 through 8 were used for analysis with the accumulation 
model and NONMEM. 
Varea was taken to be the mean of the values obtained 
after the first and last dose for the respective parameters. 
In the second stage, the mean population parameters 
were estimated by combining the corresponding indi- 
vidual estimates. In light of the pharmacostatistical 
model used for NONMEM analysis (see below), the 
geometric mean of the individual estimates was used 
to estimate the population mean parameter. Estimates 
of the interindividual random effect parameters were 
obtained by calculating the standard deviations of the 
logarithms of the corresponding fixed effect parameters. 
A confidence interval for each fixed effect parameter 
is obtained from the exponentials of the end points of 
the usual 95% confidence interval for a mean computed 
from the logarithms of the individual estimates. There 
is no appropriate method to compute 95% confidence 
intervals for random interindividual effect parameters. 
Accumulation model. The 12 trough levels (Fig. 1) 
measured from each subject during the multiple-dosing 
regimen were fit to Eq. 1: 
= (1 (1) 
where is the trough concentration measured at 
time t in the ith subject, C,1 is the average steady- 
state trough concentration for the ith subject, t is the 
time (in hours) of the sampling of C,, measured 
from the start of the multiple-dosing regimen, where 
0 < t < time of the last measured concentration, and 
kc,, is the Ice in the ith subject. 
NONMEM. The trough levels (Fig. 1) measured 
from each subject during the multiple-dosing trial were 
combined and analyzed by NONMEM. To evaluate the 
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ability of NONMEM to estimate population pharmaco- 
kinetic parameters from fragmentary data, the number 
of trough levels for each subject was progressively re- 
duced by the random removal of trough levels from 
each individual. In this fashion, three data sets were 
created: the original data set, containing 12 trough 
levels per subject (Data-1); a second data set, containing 
six trough levels per subject (Data-2); and a third data 
set, containing three trough levels per subject (Data-3). 
Ten subjects were included in each data set. Population 
pharmacokinetic parameters of alprazolam were esti- 
mated for each data set by NONMEM and were com- 
pared with the results of the STS approach and the 
accumulation model. 
Pharmacokinetic model. The pharmacokinetics of 
alprazolam in plasma are described by a one-compart- 
ment open model with first-order elimination. Drug ab- 
sorption is modeled as a zero-order infusion over a 1.5- 
hour period, the average time to peak reported in a 
previous study.9 This simple pharmacokinetic model 
was required because of the nature of the sampling 
schedule (only trough concentrations were available; 
see Discussion). To assess the influence of the value 
selected for the duration of infusion, several values 
between 0.5 and 2.5 hours were selected and the fits 
to the data were compared. Bioavailability of the drug 
in all data analysis methods is assumed to be unity.' 
The pharmacokinetic model is cast in a recursive form, 
as described previously,' because of the repetitive na- 
ture of the dosing history. The pharmacokinetic param- 
eters to be estimated are CL and Varea. 
Statistical model. Unlike the standard approach 
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Table I. Comparison of methods for the estimation of population pharmacokinetic parameters of alprazolam 
NA = Not available; CI = confidence interval; = not calculated. 
*Geometric mean. 
"ICalculated from estimates of CL and V... 
to pharmacokinetic analysis, NONMEM requires that 
an explicit statistical model be supplied. This statis- 
tical model must account for interindividual variation 
in pharmacokinetic parametersin this case, CL and 
Vareaand for residual error. The latter represents un- 
certainty in the relationship between the plasma con- 
centration predicted by the phannacokinetic model 
and the respective measured values, and is modeled 
by Eq. 2: 
ln(C,) = + (2) 
where ln(C,) is the logarithm of the ith measured plasma 
concentration in the jth individual and ln(C,) is the 
logarithm of the corresponding predicted concentration 
resulting from the pharmacokinetic model. The E, val- 
ues are independent, identically distributed statistical 
errors with mean zero and variance cr2. By modeling 
the logarithms of the drug concentrations, we state that 
the error intervening between the observed and pre- 
dicted concentrations increased in proportion to the 
measured concentration, a phenomenon frequently ob- 
served in practice. The model in Eq. 2 should be re- 
garded as only an approximation to what is undoubtedly 
a more complex error model, because E, must represent 
all uncertainty caused by intraindividual time variation 
in CL and Varea, phannacokinetic model misspecifica- 
tion, analytic errror in measurement of plasma concen- 
trations, and errors in the reported time of dosing or 
sampling for drug level determination. 
For interindividual variation, we assume that ln(CL,) 
= ln(CL) + 11C11 and ln(Var) = ln(Varea) + ivareao, 
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where CL and Va,. are the population mean values and 
the values are individual random pertubations from 
these predictions that are independent and identically 
distributed, with mean zero and variances equal to w2 
and wvarea2, respectively. These statistical models are 
written in logarithmic terms so that (1) the individ- 
ual parameters must be greater than zero, and (2) if 
a symmetric distribution is assumed for the 
distribution of individual parameters is skewed to the 
right. 
Under the additional assumption of zero covariances 
among the individual parameters, there are five popu- 
lation parameters for this pharmacostatistical model: 
CL, Varea OCL2, COVarea2 and 1:3-2. 
RESULTS 
Table I summarizes our results. The estimate of the 
population mean CL by the STS approach is 0.06 L/ 
hr/kg (95% confidence interval 0.03 to 0.12 L/hr/kg), 
which is identical to the estimate of CL by NONMEM, 
namely 0.06 L/hr/kg (95% confidence interval approx- 
imately 0.05 to 0.07 L/hr/kg). Note that the NONMEM 
estimates remain stable, along with the 95% confidence 
interval, even as the number of samples is reduced from 
12 to six to three per subject. 
Estimates of the coefficient of variation for CL are 
also similar for the two methods, approximately 29% 
for both. The 95% confidence interval for this param- 
eter by NONMEM is 16% to approximately 39%. An 
estimate for this interval is not available with the STS 
approach. 
STS 
Accumulation 
model 
NONMEM 
Data-1 Data-2 Data-3 
No. of subjects 10 10 10 10 10 
No. of samples per subject 36 12 12 6 3 
CL (L/hr/kg) 
95% CI 
0.060* 
(0.03-0.12) NA 
0.060 
(0.047-0.073) 
0.059 
(0.050-0.068) 
0.0596 
(0.049-0.070) 
Coefficient of variation (%) 
95% CI 
29 
NA NA 
29 
(16-39) 
27 
(17-34) 
28 
(17-36) 
Var (L/kg) 
95% CI 
1.05* 
(0.84-1.33) NA 
1.56 
(1.2-1.9) 
1.37 
(1.1-1.6) 
1.53 
(1.1-1.9) 
Coefficient of variation (%) 
95% CI 
14 
NA NA 
45 
(16-62) 
47 
(0-82) 
84 
(0-145) 
(%) 0.058*t 0.054* 0.038t 0.044t 0.039t 
95% CI (0.031-0.108) (0.022-0.134) (0.028-0.048) (0.035-0.053) (0.031-0.046) 
Coefficient of variation (%) 28 40 54 55 89 
95% CI NA NA 
HOURS 6 ' 16 6 16 
1DAY 
3 DAY 5 
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Fig. 2. NONMEM fit to Data-1 (12 samples per subject, 10 subjects). The solid line connects 
trough levels predicted for the average individual in this study (79.9 kg man) from population 
pharmacokinetic parameters obtained with NONMEM. The shaded area represents ± SD of in- 
traindividual variability. The area bounded by the dashed lines represents ± SD of both inter- and 
intraindividual variability. 
The estimate of the population mean Varea by the STS 
approach is 1.05 L/kg (95% confidence interval 0.84 
to 1.33 L/kg), whereas the corresponding NONMEM 
estimates are somewhat higher, 1.56 L/kg (95% con- 
fidence interval 1.2 to 1.9 L/kg), 1.37 L/kg (95% 
confidence interval, 1.1 to 1.6 L/kg), and 1.53 L/kg 
(95% confidence interval 1.1 to 1.9 L/kg) for Data-1, 
Data-2, and Data-3, respectively. Moreover, the esti- 
mates of the coefficient of variation of \Tema by NON- 
MEM are also higher (45%, 47%, and 84% for Data-1, 
Data-2, and Data-3, respectively) than the correspond- 
ing estimate by the STS approach (14%). Also note 
that the NONMEM 95% confidence interval for this 
parameter is rather large and increases as the amount 
of data decreases. 
The estimate of the Ice by the accumulation model 
(Eq. 1) is 0.054 hours", as compared with the value 
of 0.058 hours calculated from the STS estimates of 
CL and Varee. The values for ke as calculated by NON- 
MEM estimates of CL and V. are 0.038, 0.044, 0.039 
hours' for Data-1, Data-2, and Data-3, respectively. 
To determine the consequences of the use of a zero- 
order infusion process to model what is typically a first- 
order absorption process, and to assess the influence of 
a variable time to peak concentration, the data sets were 
reanalyzed with the time to peak concentration fixed at 
0.5, 1.0, 1.5, and 2.5 hours. No differences in the 
parameter estimates or the goodness of fit were found. 
Figs. 2 to 4 show the fit to the three data sets from 
the population pharmacokinetic parameters obtained 
with NONMEM. 
DISCUSSION 
Our results suggest that estimates of desired popu- 
lation pharmacokinetic parameters can be obtained di- 
rectly in patients of interest by use of the fragmentary 
information generated during phase III clinical trials or 
obtained as part of the routine clinical care of patients. 
The estimates of CL by either the STS method or 
NONMEM are identical even when only three trough 
levels per subject are used. In a study of the perform- 
ance of NONMEM in the analysis of simulated routine 
clinical data, Sheiner and Beal' demonstrated that 
NONMEM was capable of accurately estimating the 
population mean CL of a drug when as few as two 
concentrations, measured under a variety of circum- 
stances, were available per individual. Our results sug- 
gest that the above findings can be extended to the 
fragmentary data often collected as part of a phase III 
clinical trial. 
The estimates of Varea are somewhat higher with 
NONMEM analysis as compared with the STS method, 
and the precision of the estimate is worse with NON- 
MEM as indicated by the larger 95% confidence inter- 
val. This is undoubtedly the result of the sampling 
scheme. Most of the alprazolam levels used for the 
NONMEM analyses were measured at steady state, and 
because the dosing interval was less than the ti,, of the 
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drug, these levels contained very little information re- 
garding Varea. Moreover, very few levels were measured 
during the accumulation stage and no peak-trough com- 
binations were available to improve the amount of in- 
formation regarding this parameter. Identical results 
were obtained by Sheiner and Beal' in simulations with 
the trough-only sampling design; the NONMEM esti- 
mate of the population mean Varea was approximately 
20% higher than the true value. This bias can be re- 
duced, however, by obtaining measurements according 
to a more random sampling pattern. 
Although NONMEM is not able to estimate the pop- 
ulation Varea very accurately from the data available, it 
is important to note that NONMEM does provide in- 
formation that can be used to assess the precision of 
the estimate, namely the standard error of the estimate. 
NONMEM provides these values for both fixed and 
random effect parameters, and these can be used to 
estimate 95% confidence intervals for the population 
parameters. The larger the 95% confidence intervals, 
the poorer the precision of the estimate. Given the rather 
large estimates for the 95% confidence interval for Varea, 
it is clear that there is little information regarding Varea 
available in this data set and the estimate of Vaa pro- 
vided by NONMEM should not be trusted. 
To evaluate the results obtained herein properly, one 
should ideally know the true values of the population 
pharmacokinetic parameters. Unfortunately, these true 
values are rarely known, except, of course, when sim- 
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Fig. 3. NONMEM fit to Data-2 (six samples per subject, 10 subjects). The solid line connects 
trough levels predicted for the average individual in this study (79.9 kg man) from population 
pharmacokinetic parameters obtained with NONMEM. The shaded area represents -± SD of in- 
traindividual variability. The area bounded by the dashed lines represents -± SD of both inter- and 
intraindividual variability. 
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ulations are performed. However, in a study to compare 
the performance of the STS approach with NONMEM 
in the analysis of simulated experimental data, Sheiner 
and Beal' found that both approaches yield acceptable 
(nonbiased and precise) estimates for the fixed effect 
parameters. Because a large quantity of experimental 
data was used to obtain the STS estimates in the current 
study, one can assume the estimates of the fixed effect 
parameters obtained with this method represent reason- 
able estimates of the true values and can serve as a 
standard against which the NONMEM estimates can 
be compared. 
This same conclusion, however, cannot be made with 
regard to the estimates of interindividual variability. In 
the same study, Sheiner and Beal' found that the STS 
approach systematically overestimates these parame- 
ters. This is because each parameter is estimated from 
the original drug concentration-time data with some 
error. This error adds variability to the parameter es- 
timates that is not biologic in origin, resulting in an 
upward-biased estimate of interindividual variability. 
NONMEM estimates of interindividual variability tend 
to be more reliable because they are not contaminated 
with the error involved in the estimation of individual 
parameters. Although NONMEM estimates of these pa- 
rameters have been shown to be relatively unbiased. 
they are highly imprecise. This problem has been at- 
tributed to the small number of subjects generally in- 
cluded in such studies, because estimates of variability 
610 Grasela et al. 
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are considerably less precise, given a small number of 
subjects, than are estimates of means. Thus it is not 
known to what extent the estimates of interindividual 
variability obtained by either approach we used reflect 
the true values for these parameters. 
When analyzing data measured during the accumu- 
lation to steady state with a multiple-dosing regimen, 
one can use the accumulation model as presented in 
Eq. 1. Indeed, the estimate of k, obtained with this 
approach is very similar to the estimate expected on 
the basis of the results of the STS analysis of data 
obtained after the first and last dose. Use of the accu- 
mulation model, however, is limited because it allows 
only the estimation of lc, and independent estimates of 
CL and Varea are not possible under this approach. The 
NONMEM estimate of lc is (presumably) downward 
biased secondary to the estimate of Varea. As discussed 
previously, this is probably the result of the trough-only 
sampling scheme. 
NONMEM was originally developed to be used in 
the analysis of population pharmacokinetic data, data 
consisting of a dosing history and only a few measured 
drug concentrations from a large number and variety 
of individuals. Inasmuch as the data analyzed herein 
were obtained from a relatively small and homogeneous 
population, our results should not be construed as pop- 
ulation pharmacokinetic parameters. We have shown, 
however, that the data as typically collected during 
phase III and phase IV trials can be used for purposes 
10 
Fig. 4. NONMEM fit to Data-3 (three samples per subject, 10 subjects). The solid line connects 
trough levels predicted for the average individual in this study (79.9 kg man) from population 
pharmacokinetic parameters obtained with NONMEM. The shaded area represents ± SD of in- 
traindividual variability. The area bounded by the dashed lines represents ± SD of both inter- and 
intraindividual variability. Numbers identify samples from specific individuals. 
other than to document compliance. To use these data 
most efficiently, however, the traditional approaches to 
data collection in this setting, i.e. , sampling only trough 
levels, must be discarded. 
Our results, specifically the difficulty encountered in 
the estimation of Varea, and the work performed by Shei- 
ner and Beal' with simulated routine clinical data sug- 
gest that the following guidelines be used in setting up 
a population pharmacokinetic "study design." 
First, samples should be obtained at random time 
points from each individual and not according to a rigid 
experimental protocol. As we have shown, the common 
method of measuring only trough levels is unnecessarily 
restrictive and limits the information that can be ex- 
tracted from the data. Second, a minimum of two to 
four samples should be obtained from each subject, 
depending on the number of pharmacokinetic param- 
eters to be estimated. However, data that consist of only 
one sample per subject are capable of supplying addi- 
tional information when combined with more extensive 
data.' Third, a minimum of 50 to 100 subjects should 
be included and the population should be composed of 
patients representative of the population who will be 
receiving the drug for therapeutic purposes. This will 
ensure that a representative sample of patients is in- 
cluded and improve the estimates of interindividual 
variability. Finally, subjects can be receiving a variety 
of concomitant medications and diet should not be re- 
stricted; careful analysis of this data can provide in- 
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formation on a variety of possible drug-drug and drug- 
food interactions. 
In the past, data analysts have been reluctant to draw 
conclusions based on the analysis of nonexperimental 
data because of the widely recognized problems asso- 
ciated with the analysis of such data. Thus dosing guide- 
lines for newly released drugs and regulatory agency 
decisions are frequently established, in part, on the 
basis of traditional pharmacokinetic studies performed 
in normal subjects. However, recent experience with 
the drug benoxaprofeni° suggest that these rather limited 
studies are inappropriate for the establishment of dosing 
guidelines for patients and can have tragic conse- 
quences. 
Our results lend further support for the use of NON- 
MEM in the analysis of data generated during phase 
III clinical trials and in other clinical settings. The in- 
corporation of a NONMEM-like approach into phase 
III and phase IV clinical trials, in addition to the well- 
designed pilot studies currently performed, could speed 
the identification of populations at risk for toxicity 
caused by altered pharmacokinetics, and provide at least 
an initial quantification of the magnitude of this alter- 
ation. In this way we may reduce the risk of injury to 
patients exposed to new drugs. 
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